MIER2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08518(MIER2 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

**Background of MIER2 Antibody**

The MIER2 (Mesoderm Induction Early Response 2) protein, encoded by the *MIER2* gene, is a member of the MIER family of transcriptional regulators involved in chromatin remodeling and epigenetic regulation. Initially identified for its role in mesoderm induction during embryonic development, MIER2 interacts with histone deacetylases (HDACs) and other co-repressors to modulate gene expression by altering chromatin structure. It contains conserved domains, including a nuclear localization signal, an acidic transcriptional activation domain, and a chromatin-binding domain, enabling its function in transcriptional repression or activation depending on cellular context.

MIER2 plays a critical role in cell differentiation, proliferation, and apoptosis, with emerging links to cancer biology. Studies suggest it may act as a tumor suppressor or oncogene in a tissue-specific manner, influencing pathways such as Wnt/β-catenin and estrogen receptor signaling. Dysregulation of MIER2 has been implicated in breast cancer, colorectal cancer, and other malignancies.

MIER2 antibodies are essential tools for investigating its expression, localization, and interactions in vitro and in vivo. These antibodies are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to study MIER2's role in development and disease. Researchers also utilize them to explore MIER2's epigenetic regulatory mechanisms, particularly its partnership with HDAC complexes. Validation of antibody specificity remains crucial due to potential cross-reactivity with other MIER family members. Ongoing research continues to unravel MIER2's multifaceted roles, highlighting its therapeutic potential in cancer and developmental disorders.